Venetoclax is a BCL-2 inhibitor that has shown promising results in the treatment of various cancers, particularly hematologic malignancies such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It works by targeting the BCL-2 protein, which plays a key role in regulating cell death. By inhibiting BCL-2, venetoclax can induce apoptosis in cancer cells, leading to their death. Clinical trials have demonstrated that venetoclax can be effective as a single agent or in combination with other anti-cancer therapies in treating patients with these types of cancer. Research is ongoing to further explore the potential of venetoclax in other types of cancer and to optimize its use in clinical practice.